Meeting
2022 ASCO Annual Meeting
High atezolizumab antidrug antibody levels are associated with unfavorable clinical outcomes and diminished T cell responses following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.
Authors
Hong Jae Chon
Department of Medical Oncology, CHA Bundang Medical Center, Seongnam, South Korea
Hong Jae Chon , Chan Kim , Hannah Yang , Ilhwan Kim , Beodeul Kang , Hyeyeong Kim , Hyunho Kim , Won Suk Lee , Sanghoon Jung , Ho Yeong Lim , Jaekyung Cheon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Hepatobiliary Cancer
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 4105)
DOI
10.1200/JCO.2022.40.16_suppl.4105
Abstract #
4105
Poster Bd #
92
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Phase II study of atezolizumab and bevacizumab combination therapy for patients with advanced hepatocellular carcinoma who previously received systemic treatment.
First Author: Takeshi Terashima
Poster
2023 ASCO Annual Meeting
Evaluating racial disparities for patients with advanced hepatocellular carcinoma (HCC) receiving first line immunotherapy within an equal access system.
First Author: Lauren Diaz Boyle
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Phase 1b/2 study of tivozanib in combination with durvalumab in subjects with advanced hepatocellular carcinoma (Deductive): Efficacy results in previously untreated patients.
First Author: Renuka V. Iyer
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Prognostic value of the timing of immune checkpoint inhibitors infusion in patients with advanced hepatocellular carcinoma.
First Author: Alina Pascale